Oncology Peer Review On-The-Go: Barriers to Pancreatic Cancer Clinical Trial Enrollment

Podcast

The latest installment of “Oncology Peer Review On-The-Go” dissects original research published in the journal ONCOLOGY regarding potential barriers to clinical trial enrollment for patients with pancreatic cancer.

This episode of "Oncology Peer Review On-The-Go" examines an article published in the October issue of the journal ONCOLOGY, titled “Barriers to Clinical Trial Enrollment in Patients With Pancreatic Adenocarcinoma Who Are Eligible for Early-Phase Clinical Trials.”

The piece was written by Rachael Galvin, DO, MPH, Christine Chung, DO, Ella Achenbach, Oliwier Dziadkowiec, PhD, and Shiraj Sen, MD, PhD, and focuses on what keeps patients with this aggressive form of pancreatic cancer from pursuing enrollment in clinical trials. For a summary of the article, CancerNetwork spoke with Galvin, lead author of the study who is from the Swedish Medical Center in Englewood, Colorado.

For the article’s response perspective, CancerNetwork spoke with Michael Lee, MD, from The University of Texas MD Anderson Cancer Center in Houston. Lee discussed his perspective piece published on CancerNetwork titled “Barriers to Pancreatic Cancer Clinical Trials Enrollment.” The piece examines Galvin’s work and clinical trial enrollment for the disease as a whole.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

Related Videos
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
An expert from the University of California, Los Angeles suggests that the NALIRIFOX may be a beneficial treatment for patients with pancreatic ductal adenocarcinoma.
Patients with metastatic pancreatic ductal adenocarcinoma who receive NALIRIFOX tend to have more gastrointestinal toxicity while nab-paclitaxel/gemcitabine results in more cytopenias, according to an expert from University of California, Los Angeles.
An expert from the University of California, Los Angeles described the purpose and design of the phase 3 NAPOLI-3 study, assessing NALIRIFOX in metastatic pancreatic ductal adenocarcinoma.
Related Content
The liquid biopsy combining miRNA and CA19-9 had the best validation rates for detecting pancreatic ductal adenocarcinoma.

miRNA Assay May Lead to Early Detection in PDAC

April 8th 2024
Article

The liquid biopsy combining miRNA and CA19-9 had the best validation rates for detecting pancreatic ductal adenocarcinoma.

Diane M. Simeone, MD highlights the importance of multidisciplinary care, surgical practices, and early detection in pancreatic cancer care.

Diane M. Simeone, MD “Thrilled” To Be UCSD Moores Cancer Center Director

February 26th 2024
Podcast

Diane M. Simeone, MD highlights the importance of multidisciplinary care, surgical practices, and early detection in pancreatic cancer care.

Investigators are currently evaluating treatment with IMM-1-104 in pancreatic cancer and other disease types associated with the RAS pathway as part of a phase 1/2a study.

IMM-1-104 Earns FDA Fast Track Designation in Pancreatic Cancer

February 22nd 2024
Article

Investigators are currently evaluating treatment with IMM-1-104 in pancreatic cancer and other disease types associated with the RAS pathway as part of a phase 1/2a study.

Oncology Peer Review On-The-Go: Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma

Oncology Peer Review On-The-Go: Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma

May 7th 2022
Podcast

Christine Chung, DO, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® about implications of blood-based molecular markers in pancreatic adenocarcinoma.

Patients with metastatic pancreatic ductal adenocarcinoma may now receive injectable irinotecan liposome in combination with 5-fluorouracil/leucovorin and oxaliplatin in the first-line setting, which has been approved by the FDA.

Frontline NALIRIFOX Approved by FDA in Metastatic PDAC

February 13th 2024
Article

Patients with metastatic pancreatic ductal adenocarcinoma may now receive irinotecan liposome in combination with 5-fluorouracil/leucovorin and oxaliplatin in the first-line setting, which has been approved by the FDA.

Investigators of the AMPLIFY-201 trial hypothesized that ELI-002 2P may induce the expansion of functional tumor-directed KRAS-mutated specific T cells following tumor resection.

Cancer Vaccine Shows Efficacy and Safety Potential in PDAC and CRC

February 13th 2024
Article

Investigators of the AMPLIFY-201 trial hypothesized that ELI-002 2P may induce the expansion of functional tumor-directed KRAS-mutated specific T cells following tumor resection.